# COVID-19 VACCINE SAFETY AND EFFECTIVENESS

> **NCT05133609** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Federal University of Espirito Santo** · enrollment: 550 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** ChAdOx1 nCoV-19 vaccine (AZD1222)

## Key facts

- **NCT ID:** NCT05133609
- **Lead sponsor:** Federal University of Espirito Santo
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-15
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-12-30
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05133609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05133609, "COVID-19 VACCINE SAFETY AND EFFECTIVENESS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05133609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*